TheMythos investigator-sponsored clinical trial of RenalGuard included 170 enrolled patients with chronic kidney disease (CKD) who underwent elective or urgent percutaneous coronary interventions (PCI) in Italy.
The study results showed that patients who were at higher risk for renal failure and who were treated with RenalGuard while undergoing imaging procedures developed CIN at a rate 74% lower than those who were treated with overnight hydration.
The final results from the Mythos trial of RenalGuard in Italy have been published in the January 2012 issue of JACC – Cardiovascular Interventions.
PLC Systems president and CEO Mark R Tauscher said the positive results of the Mythos clinical trial demonstrate, in scientifically significant findings, that RenalGuard is a superior approach to reducing the incidence of CIN in at-risk patients.
”We believe that greater awareness of these positive scientific findings and the positive findings from the Remedial II trial will further drive the interest we are seeing from distributors, partners and customers for RenalGuard in the markets where it is available," Tauscher added.
